Ontology highlight
ABSTRACT:
SUBMITTER: Garcia-Gutierrez V
PROVIDER: S-EPMC7408792 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Journal of clinical medicine 20200715 7
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML), a significant proportion will not achieve optimal response to imatinib or second-generation tyrosine kinase inhibitors (2GTKI). For patients with inadequate response to 2GTKIs, alternative 2GTKIs or ponatinib are widely available treatment options in daily clinical practice. Treatment decisions should be guided by correct identification of the cause of treatment failure and accurate distinction between r ...[more]